# Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

**Authors:** Yasuhiro Kodera, Kazuhiro Yoshida, Mitsugu Kochi, Takeshi Sano, Wataru Ichikawa, Yoshihiro Kakeji, Yu Sunakawa, Masahiro Takeuchi, Masashi Fujii

PMC · DOI: 10.1007/s10120-024-01519-0 · 2024-06-12

## Full-text entities

- **Diseases:** gastric cancer (MESH:D013274), Stage III (MESH:D062706)
- **Chemicals:** docetaxel (MESH:D000077143), S-1 (-)

---
Source: https://tomesphere.com/paper/PMC11335771